Safety, immunogenicity and antibody persistence of a bivalent Beta-containing booster vaccine against COVID-19: a phase 2/3 trial
Spyros Chalkias(Moderna Therapeutics (United States)), Rituparna Das(Moderna Therapeutics (United States)), Stephen R. Walsh(Beth Israel Deaconess Medical Center), Rolando Pajón(Moderna Therapeutics (United States)), Xing Chen(Moderna Therapeutics (United States)), Jing Feng(Moderna Therapeutics (United States)), Jacqueline M. Miller(Moderna Therapeutics (United States)), Brett Leav(University of Maryland, Baltimore), Biliana Nestorova(Moderna Therapeutics (United States)), Darin K. Edwards(Moderna Therapeutics (United States)), Shishir Khetan(Meridian Clinical Research), Frank J. Dutko(Moderna Therapeutics (United States)), Lindsey R. Baden(Brigham and Women's Hospital), Ying Chang(Moderna Therapeutics (United States)), Frank Eder(University of Maryland, Baltimore), David C. Montefiori(Duke University), Brandon Essink(Velocity Clinical Research (United States)), Bethany Girard(Moderna Therapeutics (United States))
Cited by 144
Related Papers
Tracking Changes in SARS-CoV-2 Spike: Evidence that D614G Increases Infectivity of the COVID-19 Virus
|Cell|2020|4.5k
Persistence and Evolution of SARS-CoV-2 in an Immunocompromised Host
|New England Journal of Medicine|2020|1.4k
Two Randomized Phase 3 Studies of Aducanumab in Early Alzheimer's Disease
|The Journal of Prevention of Alzheimer s Disease|2022|1.3k